Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VIJAY K GUNUGANTI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1073535076
CMS profile
184290
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$289,496.21

249 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VIJAY K GUNUGANTI

NPI 1073535076 · CMS profile ID 184290

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073535076?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VIJAY K GUNUGANTI, NPI 1073535076, CMS profile ID 184290. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073535076?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VIJAY K GUNUGANTI, NPI 1073535076, CMS profile ID 184290. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073535076?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VIJAY K GUNUGANTI, NPI 1073535076, CMS profile ID 184290, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 249 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1073535076?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

249 matching records · $289,496.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 249 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 249.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $112.5910/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988424135 CMS
Janssen Pharmaceuticals, Inc $5.5010/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987971633 CMS
Janssen Pharmaceuticals, Inc $10.6610/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987971699 CMS
Regeneron Healthcare Solutions, Inc. $65.2010/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999198171 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,462.5010/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055396751 CMS
AstraZeneca Pharmaceuticals LP $102.1210/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014850929 CMS
Bayer Healthcare Pharmaceuticals Inc. $68.3810/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000698611 CMS
Janssen Biotech, Inc. $18.0210/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988424229 CMS
Bayer Healthcare Pharmaceuticals Inc. $76.0010/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000698755 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.7310/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000690513 CMS
Bayer Healthcare Pharmaceuticals Inc. $48.1010/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000698407 CMS
Bayer Healthcare Pharmaceuticals Inc. $75.7210/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000698743 CMS
Bayer Healthcare Pharmaceuticals Inc. $102.5510/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000698975 CMS
Bayer Healthcare Pharmaceuticals Inc. $134.4110/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000699377 CMS
Bayer Healthcare Pharmaceuticals Inc. $295.3110/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000699793 CMS
Bayer Healthcare Pharmaceuticals Inc. $399.8810/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000699947 CMS
Bayer Healthcare Pharmaceuticals Inc. $7,150.0010/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000701985 CMS
Merck Sharp & Dohme LLC $101.2510/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048564183 CMS
Exelixis Inc. $124.3910/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044606757 CMS
Janssen Pharmaceuticals, Inc $300.0010/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987971617 CMS
Bayer Healthcare Pharmaceuticals Inc. $7,020.0010/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000701963 CMS
AstraZeneca Pharmaceuticals LP $2,150.0010/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015888857 CMS
Regeneron Healthcare Solutions, Inc. $501.9009/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999198167 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.5209/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000689847 CMS
Janssen Biotech, Inc. $3,575.0009/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988424125 CMS
Janssen Scientific Affairs, LLC $73.9009/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988467285 CMS
Bayer Healthcare Pharmaceuticals Inc. $188.8009/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000699543 CMS
E.R. Squibb & Sons, L.L.C. $600.0009/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015754631 CMS
AstraZeneca Pharmaceuticals LP $121.8609/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011251979 CMS
AstraZeneca Pharmaceuticals LP $600.0009/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015044523 CMS
E.R. Squibb & Sons, L.L.C. $0.8609/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015754569 CMS
E.R. Squibb & Sons, L.L.C. $1.1709/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015754573 CMS
Janssen Biotech, Inc. $121.8209/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988424113 CMS
Bayer Healthcare Pharmaceuticals Inc. $73.9409/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000698663 CMS
Bayer Healthcare Pharmaceuticals Inc. $74.9909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000698703 CMS
Janssen Pharmaceuticals, Inc $98.9909/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987971691 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.4409/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000692333 CMS
Janssen Biotech, Inc. $15.5209/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988424239 CMS
Regeneron Pharmaceuticals, Inc. $289.0009/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000013757 CMS
Regeneron Pharmaceuticals, Inc. $3,468.0009/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000013765 CMS
Regeneron Pharmaceuticals, Inc. $3,468.0009/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000013779 CMS
Regeneron Pharmaceuticals, Inc. $501.9009/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000013789 CMS
Regeneron Pharmaceuticals, Inc. $104.5509/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000013799 CMS
Regeneron Pharmaceuticals, Inc. $101.9109/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000013809 CMS
Regeneron Pharmaceuticals, Inc. $144.7909/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000013819 CMS
Janssen Pharmaceuticals, Inc $18.4209/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987971707 CMS
E.R. Squibb & Sons, L.L.C. $1.5408/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015754593 CMS
Medtronic, Inc. $141.5908/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018964283 CMS
Bayer Healthcare Pharmaceuticals Inc. $315.8108/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000699857 CMS
Janssen Pharmaceuticals, Inc $27.7508/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987971683 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $116,650.89 121
PY2020 $134,478.28 162
PY2021 $169,902.16 194
PY2022 $256,632.86 275
PY2023 $289,496.21 249
PY2024 $215,084.68 178
PY2025 $333,756.56 308

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $94,223.91 28
PY2024 Principal investigator $222,904.33 22
PY2023 Principal investigator $31,006.10 13
PY2022 Principal investigator $30,867.56 19
PY2021 Principal investigator $97,950.03 80
PY2020 Principal investigator $165,343.50 296
PY2019 Principal investigator $18,926.62 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,346.00 12/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407441
Principal investigator 1 Janssen Research & Development, LLC $299.00 11/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406957
Principal investigator 1 Janssen Research & Development, LLC $476.00 11/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407222
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 10/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107688
Principal investigator 1 Janssen Research & Development, LLC $291.00 09/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408188
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107683
Principal investigator 1 Janssen Research & Development, LLC $649.00 07/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406963
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175404919
Principal investigator 1 Janssen Research & Development, LLC $5,142.00 07/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407950
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 05/30/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107676
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 05/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107693
Principal investigator 1 GlaxoSmithKline, LLC. $2,945.88 05/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192110043
Principal investigator 1 Janssen Research & Development, LLC $299.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405109
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406862
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407490
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 05/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408215
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,500.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185540701
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,150.00 04/30/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185540697
Principal investigator 1 Janssen Research & Development, LLC $4,100.00 04/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175408311
Principal investigator 1 Janssen Research & Development, LLC $4,346.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407310
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 02/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175404855
Principal investigator 1 Janssen Research & Development, LLC $1,547.00 02/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175405184
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 02/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175406252
Principal investigator 1 Janssen Research & Development, LLC $299.00 02/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175407227
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 02/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCHLLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192107700
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,600.00 01/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185540699
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,810.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185540695
Principal investigator 1 AstraZeneca UK Limited $28,497.03 01/14/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185540693